Related Experiment Video
Updated: Feb 10, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
Checkpoint blockade in the treatment of breast cancer: current status and future directions
Lironne Wein1, Stephen J Luen1, Peter Savas1
1Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Abstract:
There is now accumulating evidence that the host immune system plays an important role in influencing response to treatment and prognosis in breast cancer. Immunotherapy with immune checkpoint inhibitors is a promising and rapidly growing field of interest in many solid tumours, including breast cancer. Trials to date have largely focused on metastatic triple-negative disease, a genomically unstable subtype of breast cancer that is believed to be the most immunogenic and following the development of treatment resistance, has limited treatment options and a particularly poor prognosis. Both checkpoint inhibitor monotherapy and combinations with chemotherapy are being investigated. In this review, we discuss the current evidence for PD-1/PD-L1 blockade in metastatic triple-negative breast cancer (TNBC), HER2+ breast cancer and ER+ disease, as well as the emerging evidence for use in the early-stage (neoadjuvant) setting. We also propose potential ways of improving responses to checkpoint blockade in breast cancer.
Insights
Immune checkpoint inhibitors show promise for breast cancer treatment, particularly advanced triple-negative disease. Research is exploring their use alone or with chemotherapy across various breast cancer subtypes and early-stage settings.
Area of Science:
- Oncology
- Immunology
- Cancer Therapeutics
Background:
- Host immune system significantly impacts breast cancer treatment response and prognosis.
- Immune checkpoint inhibitors (ICIs) are a rapidly advancing therapeutic strategy for solid tumors, including breast cancer.
- Metastatic triple-negative breast cancer (TNBC) is highly immunogenic, often develops treatment resistance, and has a poor prognosis, making it a key focus for immunotherapy.
Purpose of the Study:
- To review current evidence on PD-1/PD-L1 blockade in various breast cancer subtypes.
- To discuss the emerging role of ICIs in early-stage (neoadjuvant) breast cancer.
- To explore strategies for enhancing patient responses to checkpoint blockade therapy.
Main Methods:
- Review of existing clinical trial data and scientific literature on immune checkpoint inhibitors in breast cancer.
- Analysis of PD-1/PD-L1 blockade efficacy in metastatic triple-negative, HER2+, and ER+ breast cancer.
- Evaluation of neoadjuvant immunotherapy approaches and combination strategies.
Main Results:
- Accumulating evidence supports the role of the immune system in breast cancer outcomes.
- Clinical trials have primarily investigated ICIs in metastatic TNBC, with monotherapy and combination regimens being explored.
- Emerging data suggests potential for ICIs in HER2+ and ER+ disease, as well as in the neoadjuvant setting.
Conclusions:
- Immune checkpoint inhibitors represent a promising therapeutic avenue for breast cancer, especially TNBC.
- Further research is needed to optimize ICI use across different breast cancer subtypes and stages.
- Developing strategies to improve response rates to checkpoint blockade is crucial for advancing breast cancer treatment.
Related Concept Videos
Neuromuscular Junction And Blockade
Treatment Resistant Cancers
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Marcia's Theory of Identity Status
Electrical Current
Directing Effect of Substituents: meta-Directing Groups

